Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial

Metastatic and chemoresistant melanoma can be a good target of immunotherapy because it is an intractable cancer with a very poor prognosis. Previously, we tested a dendritic cell (DC)-based phase I vaccine, and confirmed that it was safe. In the present study, we performed a phase II trial of a DC...

Descripción completa

Detalles Bibliográficos
Autores principales: OSHITA, CHIE, TAKIKAWA, MASAKO, KUME, AKIKO, MIYATA, HARUO, ASHIZAWA, TADASHI, IIZUKA, AKIRA, KIYOHARA, YOSHIO, YOSHIKAWA, SHUSUKE, TANOSAKI, RYUJI, YAMAZAKI, NAOYA, YAMAMOTO, AKIFUMI, TAKESAKO, KAZUTOH, YAMAGUCHI, KEN, AKIYAMA, YASUTO
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2012
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583475/
https://www.ncbi.nlm.nih.gov/pubmed/22895835
http://dx.doi.org/10.3892/or.2012.1956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583475/
https://www.ncbi.nlm.nih.gov/pubmed/22895835
http://dx.doi.org/10.3892/or.2012.1956

Ejemplares similares